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Skeletal Site-specific Changes in 
Bone Mass in a Genetic Mouse 
Model for Human 15q11-13 
Duplication Seen in Autism
Kirsty E. Lewis1,5, Kunal Sharan1,6, Toru Takumi2,3 & Vijay K. Yadav  1,4
Children suffering from autism have been reported to have low bone mineral density and increased 
risk for fracture, yet the cellular origin of the bone phenotype remains unknown. Here we have utilized 
a mouse model of autism that duplicates 6.3 Mb region of chromosome 7 (Dp/+) corresponding to 
a region of chromosome 15q11-13, duplication of which is recurrent in humans to characterize the 
bone phenotype. Paternally inherited Dp/+ (patDp/+) mice showed expected increases in the gene 
expression in bone, normal postnatal growth and body weight acquisition compared to the littermate 
controls. Four weeks-old patDp/+ mice develop a low bone mass phenotype in the appendicular but 
not the axial skeleton compared to the littermate controls. This low bone mass in the mutant mice was 
secondary to a decrease in the number of osteoblasts and bone formation rate while the osteoclasts 
remained relatively unaffected. Further in vitro cell culture experiments and gene expression analysis 
revealed a major defect in the proliferation, differentiation and mineralization abilities of patDp/+ 
osteoblasts while osteoclast differentiation remained unchanged compared to controls. This study 
therefore characterizes the structural and cellular bone phenotype in a mouse model of autism that can 
be further utilized to investigate therapeutic avenues to treat bone fractures in children with autism.
The skeleton is an organ system in the body that performs many vital functions1. On one hand, it protects many 
soft organs such as brain and heart, and on the other it serves as an endocrine organ to influence function of 
other organs such as pancreas, testis and brain1, 2. Major component of the mature skeleton are bones, which are 
continuously remodelled, through a process known as bone remodelling, throughout life to perform these vital 
functions. Bone remodelling is carried out by two cell types, osteoblasts and osteoclasts3, 4. Osteoblasts are the 
mono-nucleated cells of mesenchymal origin that deposit new bone matrix while the osteoclasts are multinucle-
ated cells of hematopoietic origin that degrade the old bone matrix5–7. These two cells function as a bone remodel-
ling unit to replace the old bone matrix with a new one to maintain the mechanical strength of the skeleton. Bone 
remodelling is tightly regulated via a complex process, which is only now beginning to be understood5–8. It is 
affected by variety of cues, which are environmental, autocrine/endocrine, and genetic in nature. An imbalance in 
these cues leads to bone diseases characterized by a low bone density and an increased risk of fractures1–8. Many 
diseases with complex aetiology have long been known to be associated with low bone density and increased risk 
of fractures yet the underlying mechanisms remain unclear.
Autism is a neurodevelopmental disorder characterized by impaired language skills and communication, as 
well as repetitive and stereotypic patterns of behavior9. Autism is one of the most heritable psychiatric disorder 
suggesting that genetic factors play a large role in its development or manifestation of symptoms10, 11. Psychiatric 
symptoms in autism appear during early life, as early as 6 months of age, and persist throughout life9. Besides 
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the psychiatric problems children with autism are often found to have low bone density and increased risk of 
fractures12–15. The fact that like autism, genetics and heritability plays an important role in the establishment 
and maintenance of bone density suggests that common factors could be involved in regulating bone density 
and autism16. However, besides genetic factors environment also plays an important role in regulating different 
phenotypes in autism spectrum disorders viz., physical exercise and nutrition. In the past, several knockout mice 
have been created to investigate different phenotypes in autism, but the molecular mechanism responsible for the 
pathophysiology of autism and its associated metabolic diseases is far from complete17–25. The above facts under-
score that we need to increase our knowledge of bone development in autism in an animal model so that we can 
optimize dysregulated bone homeostasis in children with autism.
A genetic mouse model had been created by us earlier to investigate the psychiatric symptoms in autism fol-
lowing duplication of a region on the chromosome 15 i.e., 15q11.2-13.126. Duplication of this chromosomal region 
is the recurrent cytogenetic aberration associated with autism, which occurs in up to 5% of patients9–11, 27–33. 
On the basis of conserved human/mouse linkage, a mouse model with a 6.3 Megabase (Mb) duplication of mouse 
chromosome 7, mirroring the human chromosome 15q11.2-13.1 duplication was created through sequential 
tragetting of the embryonic stem cells26. The paternally inherited Dp/+ mouse genetic model (referrred in this 
study as patDp/+ from now on) faithfully recapitulates several behavioural phenotypes observed in the autism 
patients and provides us an opportunity to characterize the bone phenotype in these mice. Here we report that 
patDp/+ mice display a low bone mass phentopye and charatcerise the architectural and cellular bone parameters 
in these mutant mice.
Results
Generation and analysis of mice with paternally duplicated autism loci on chromosome 7 
(patDp/+ mice). The duplication of the region of human chromosome 15q11-13 was modelled in mouse 
through interstitial duplication of mouse chromosome 7 corresponding to the region between common break-
points in human chromosome 15q11-13 by chromosomal engineering (Fig. 1A) as described previously26. To 
generate the experimental cohort of mice for analysis male patDp/+ mice were breed with female +/+ C57Bl6/N 
Figure 1. Generation and analysis of a duplicated region of chromosome 7 (Dp/+) in mice. (A) Schematic 
representation of the genomic regions in the human and mouse genomes showing the details of conserved 
linkage in human 15q11-13 and mouse chromosome 7. The duplicated region is marked by the insertional site 
for the 2 LoxP (Adapted from Nakatani et al., Cell 2009). (B) Schematic represetation of the breeding strategy 
used to generate patDp/+ and corresponding control WT (+/+) mice. (C) Genotyping PCR analysis on the 
tail genomic DNA to identify the +/+ and patDp/+ mice. The gel is the full length gel and lanes have not been 
cropped or stitched. (D) Expected expression levels in the +/+ and patDp/+ mice for the genes present in 
the duplicated region. (E) qPCR analysis of genes in the duplicated region and 2 genes that lie outside of the 
duplicated region in the long bone from +/+ and patDp/+ mice. Paternally expressed genes are marked with 
blue, maternally expressed with red and nonimprinting genes are marked with green. Dotted lines represent 
boundaries of the chromosomal rearrangement. (F–H) Body weight (F) % Fat pad weight (G) and nasal to anal 
length (H) analysis in +/+ and patDp/+ mice. n = 8–10 mice per group.
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mice and genotyped using PCR on the genomic DNA, these mice are labelled as patDp/+ mice from here on 
(Fig. 1B,C).
The 6.3 Mb duplication region in the patDp/+ mice includes the region of genomic imprinting and has the fol-
lowing genes: Herc2, Gabrγ3, Gabrα5, Gabrβ3, Atp10a, Ube3a, Snrpn, Ndn, Magel2 and Mkrn3. Because the gene 
expression is expected to vary depending on the tissue type, imprinting status and mode of inheritance as shown 
in Fig. 1D, relative gene expression was assessed by quantitative RT-PCR in the bones from patDp/+ mice relative 
to WT mice (Fig. 1E). Moreover, the expression changes in these genes in the patDp/+ mice has been assessed 
earlier in the brain and therefore it was imperative for us to establish their expression levels in the bones of these 
mice to further investigate their possible involvement in the cellular phenotype in the bone. In the bone, Herc2, 
Gabrγ3, Gabrα5, Gabrβ3, Snrpn, Ndn, Magel2 and Mkrn3 genes in the duplicated region were increased in the 
expression whereas Atp10a and Ube3a did not show a significant change in the expression (Fig. 1E). As expected 
Tubgcp5 and Chrna7, which are located outside the duplicated region, did not show any significant difference 
in their expression levels (Fig. 1E). patDp/+ mice bred normally and were fertile and as reported previously26 
showed normal body weight compared to wild-type (WT) mice (Fig. 1F–H). *P < 0.05, **p < 0.01, ***p < 0.001.
Analysis of bone volume and architecture in patDp/+ mice. Having confirmed that the patDp/+ 
mice have the expected expression changes in bone for the genes present in the duplicated region we next ana-
lyzed whether significant differences in specific bone parameters exist between WT and patDp/+ mice. As the 
bone composition (cortical versus trabecular) in mammals differs depending on the skeletal site analyzed we 
decided to analyze two different skeletal sites, long bone and vertebra. We selected tibia as a representative long 
bone for μCT analysis and analyzed them at two different locations, proximal region for changes in the trabecular 
parameters and mid-shaft for changes in the cortical parameters. For trabecular bone analysis, we selected lumbar 
4 vertebrae as a representative trabecular bone rich site. We first performed analysis on the tibia bones by μCT. 
As shown in Fig. 2A, the proximal tibias of 4 weeks-old female patDp/+ mice exhibited significant decreases in 
the bone volume over total volume % (BV/TV%), bone surface per total volume % (BS/TV%), trabecular num-
ber (Tb.N.) and thickness (Tb.Th.) and a tendency to have higher trabecular separation (Tb.Sp.) relative to WT 
littermate controls. The differences in these parameters ranged between 2.7% and 17%. We next assessed changes 
in cortical parameters, thickness and porosity, at tibia mid-shaft. Cortical thickness tended to be on the lower side 
(ns) and cortical porosity on the higher side (ns) in the patDp/+ relative to WT littermates (Fig. 2B). μCT analysis 
of 4 weeks-old male patDp/+ mice showed a compromised bone architecture like the female mice with significant 
decreases in the BV/TV%, BS/TV%, Tb.N. and Tb.Th. (Fig. 2C). The mutant animals also had a tendency towards 
Figure 2. Low bone mass in the long bone but not spine of 4 week-old patDp/+ mice. (A) μCT analysis of 
proximal tibia in 4 week-old +/+ and patDp/+ mice. (B) μCT analysis of tibial mid-shaft in 4 weeks-old +/+ 
and patDp/+ mice. (C) μCT analysis of proximal tibia in 4 weeks-old +/+ and patDp/+ male mice. (D) μCT 
analysis of proximal tibia in 12 weeks-old +/+ and patDp/+ mice. (E,F) Von Kossa staining of histological 
sections of lumber 3 vertebra in 4 weeks (E)- and 12 weeks-old (F) +/+ and patDp/+ mice. *P < 0.05. Values 
are mean ± SEM. n = 8–10 mice were utilized per group. All mice were females except in the panel C where 
male mice have been used. Abbreviations used are Bone volume over total volume % (BV/TV%); Bone surface 
over total volume % (BS/TV%); Trabecular separation (Tb.Sp); Trabecular number (Tb.N.); Trabceular 
thickness (Tb.Th.); Cortical thickness (Ct.Th.) and Cortical porosity (Ct.Po.).
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higher Tb.Sp. (Fig. 2C). In contrast to the significant changes in the bone phenotype in the 4 weeks-old mice, 12 
weeks-old patDp/+ mice did not display any changes in the bone architecture in tibia (Fig. 2D). We next analyzed 
vertebra through classical non-demineralized histology after methyl methacrylate-embedding, a standard tech-
nique used to assess vertebral histopathology. In contrast to the compromised bone structure in the tibia, analysis 
of vertebra collected from 4 weeks- and 12 weeks-old patDp/+ mice through histology and histomorphometry 
did not reveal any significant difference in the bone volume over total volume % between WT and mutant mice 
indicating that bone mass in the vertebral column is not affected in the patDp/+ mice (Fig. 2E,F).
Histomorphometric analysis of 4 weeks-old WT and patDp7/+ female mice. Because we observed 
a compromised bone volume, surface and trabecular parameters in the patDp/+ mice in the long bones, it was of 
interest to further examine this bone phenotype at the cellular level. Histological and histomorphometric analysis 
was performed on femurs at the femoro-tibial joint of WT and patDp/+ mice at 4 weeks of age. This analysis, as 
shown in Fig. 3A, clearly demonstrates that there is a significant decrease in the trabecular bone of patDp/+ mice 
relative to WT littermates. In light of the striking defects observed in the histological analysis of femurs from 
female patDp/+ mice with regard to bone mass, we next determined if this defect was at least in part due to differ-
ences in the number of osteoblasts or osteoclasts lining the bone surface of these animals (Fig. 3B,C).
We first analyzed changes in the osteoblast numbers and function. As shown in Fig. 3B, there was a significant 
decline in the number of osteoblasts per trabecular area. This accounted for a significant decrease in the osteoid 
parameters as well. Osteoid is the protein matrix secreted by osteoblasts. Both osteoid thickness and osteoid 
volume/total volume % was significantly decreased in the patDp/+ mice relative to WT littermates (Fig. 3B). 
This decrease in the osteoblast numbers and function was also reflected in the serum marker of osteoblast func-
tion, osteocalcin, which was decreased by 19% in the patDp/+ mice (Fig. 3B). In contrast to the observed defect 
in the osteoblast parameters there was no significant difference in the osteoclast surface/bone surface in the 
patDp/+ mice relative to WT littermates (Fig. 3C). Accordingly, serum marker of bone resorption, collagen type 
1 cross-linked C-telopeptide (Ctx) was not altered in the patDp/+ mice relative to WT littermates (Fig. 3C).
Overall, these findings suggest that female patDp/+ mice are osteopenic mainly due to a significant decrease 
in osteoblast numbers and function and not likely due to a large difference in the osteoclast parameters.
Cell autonomous decrease in osteoblast parameters in patDp/+ mice. The decrease in osteoblast 
numbers and functions observed in the patDp/+ mice in vivo through skeletal histology and histomorphometry 
raises the question whether osteoblasts in these mice have a cell autonomous defect. This osteoblast defect could 
be either in the ability of these mutant osteoblasts to proliferate, differentiate or deposit the mineral matrix or 
all of the aforementioned parameters. To test this contention, we next utilized primary osteoblasts isolated from 
calvarias of the WT and patDp/+ mice and tested them for proliferation, differentiation and mineralization using 
in vitro assays (Fig. 4).
To determine if osteoblast proliferation was affected by patDp/+ mutation, we measured the number of cells 
actively synthesizing DNA by BrdU incorporation in vitro (Fig. 4A). Analysis of proliferation of osteoblasts iso-
lated from WT and patDp/+ mice revealed a 40% decrease in proliferation of patDp/+ osteoblasts compared to 
their WT counterparts (Fig. 4A). Molecularly this decrease in proliferation of patDp/+ osteoblasts was associated 
with a decrease in the expression of Cyclins in these cells (Fig. 4B).
We next determined whether differentiation potential of osteoblasts was affected by patDp/+ mutation using 
two different assays, alkaline phosphatase (ALP) activity assay and marker gene expression analysis. ALP activity 
was decreased by ~50% in the patDp/+ mice osteoblasts compared to the WT counterparts (Fig. 4C). Analysis 
of gene expression markers of osteoblast differentiation6 revealed a 35–50% decrease in the expression of Runx2, 
Atf4, Osx, Alp and Col1a1 (Fig. 4D).
Lastly, we looked at the effect of patDp/+ mutation on the osteoblasts function by analyzing changes in min-
eralization ability of osteoblasts isolated from the WT and patDp/+ mice. As shown in Fig. 4E qualitative analysis 
Figure 3. Isolated osteoblast defect contributes to the low bone mass phenotype in the long bone of patDp7/+ 
mice. (A) Von Kossa staining of histological section and bone volume over total volume % (BV/TV%) analysis 
in +/+ and patDp/+ mice. (B) Analysis of osteoblast numbers, osteoid thickness and osteoid volume per total 
volume % in +/+ and patDp/+ mice. (C) Analysis of osteoclast surface per bone surface and Ctx levels in 4 
week-old +/+ and patDp/+ mice. *P < 0.05. Arrow heads indicate location of respective cells in the sections. 
Values are mean ± SEM. n = 8–10 mice per group. All mice were females.
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of mineralization using Alizarin red assay revealed a major decline in the mineralization potential of patDp/+ 
osteoblasts compared to the WT counterparts (Fig. 4E).
We next assayed for the ability of patDp/+ mutation to affect differentiation of bone marrow precursor cells 
into tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts in vitro. As can be seen in Fig. 4F-G there was 
no significant difference in the osteoclast differentiation at the level of the multinucleated osteoclast formation 
(Fig. 4F) or the expression Trap in these cells (Fig. 4G).
Taken together these in vitro results demonstrate that patDp/+ mutation directly, and very potently, affects 
various aspects of osteoblast biology, but does not affect differentiation of osteoclasts.
Discussion
In humans, it is well known that autism and autism associated disorders are often associated with a low bone 
density, but the bone phenotype has not been characterized in an animal model to pave a way towards future 
therapeutic developments to treat bone disorders in this disease12–15. The principal aim of our study was to char-
acterize the bone phenotype in a mouse genetic model of autism at the structural, cellular and molecular levels.
The Dp/+ mice have been created with a 6.3 Mb duplication in chromosome 7 in a region that is the recur-
rent genetic abnormality in autism. Using a battery of tests, it has been documented that patDp/+ mice display 
many of the characteristic features of autism viz., social and anxiety abnormalities26. We therefore used patDp/+ 
mice for the detailed characterization of skeletal phenotype. We report that 4 weeks-old patDp/+ mice display 
structural defects in the long bones in the trabecular compartment and show a tendency towards reduced cortical 
integrity in the cortical compartment. This low bone mass phenotype was found to be associated with a defect in 
the bone formation parameters while bone resorbing cell numbers remained relatively unaltered. In contrast to 
changes in the long bone, bone mass was not affected in the vertebral column with the patDp/+ mutation. In vitro 
analysis of osteoblast and osteoclast cultures showed the patDp/+ mutant osteoblasts have intrinsic defects in 
multiple parameters compared to their WT counterparts. The above facts point towards the genes present in the 
patDp/+ region affecting the osteoblast functions through their expression in the osteoblasts.
We observed a decrease in the bone mass and architecture in the long bone and not in the vertebra of the 
patDp/+ mice whereas in humans with this disease the bone phenotype is present in both the sites12–16. There are 
important differences in the forces that determine bone deposition at different skeletal sites in mice and humans 
that may explain this underlying phenotypic differences observed34, 35. In humans both the long bones and the 
vertebral column are load bearing bones and show changes in bone structure and mass with changes in load34. In 
contrast in rodents the load bearing bones are only the long bones and not the vertebral column34. Changes in the 
endocrine environment and intrinsic osteoblast defects often lead to changes in both the long bones and vertebral 
bone mass; in contrast if the mutation in osteoblasts is affecting their ability to respond to mechanical stimuli 
coupled with hormonal/local changes then there is often an isolated change in bone mass in the long bone34–36. 
Our observation of a decreased bone mass in the long bone and not the vertebral column in the patDp/+ mice 
Figure 4. Osteoblast proliferation, differentiation and function is compromised in patDp/+ mice. (A) BrdU 
incorporation assay in +/+ and patDp/+ calvarial osteoblasts. (B) Real-time PCR analysis of Cyclins in WT 
and patDp/+ calvarial osteoblasts. (C) Alkaline phosphatase activity assay in +/+ and patDp /+ calvarial 
osteoblasts. (D) Real-time PCR analysis of osteoblast marker genes in +/+ and patDp/+ osteoblasts. (E) 
Alizarin red staining in +/+ and patDp/+ calvarial osteoblasts cultured for 21 days. (F,G) Trap staining analysis 
(F) and Trap gene expression (G) in differentiated osteoclasts from +/+ and patDp/+ mice. *P < 0.05. Values 
are mean ± SEM. n = 5–8 per group.
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therefore points toward the intrinsic defect in patDp/+ osteoblasts that hampers their ability to proliferate, differ-
entiate and mineralize and likely compromises their ability to respond to mechanical stimuli.
There are 10 genes present in the region that is duplicated in the patDp/+ mice and although it is difficult at 
the present time to point towards any particular gene ultimately responsible for the low bone mass phenotype in 
this model, prior studies point towards few of these genes being involved in the bone phenotype. We will now dis-
cuss the genes that may possibly be associated with a low bone mass in patDp/+ mice. Loss of function of Mkrn3 
has been shown to be associated with advanced bone age in humans and therefore an increase in its expression, 
as observed in our model, may negatively affect bone mass37. Mouse and human genetic studies have shown that 
NECDIN (NDN), MAGEL2, and SNRPN contribute to the complex neurogenetic imprinting disorder Prader–
Willi-Syndrome (PWS). The symptoms of PWS, which include hyperphagia, severe obesity, hypogonadism, and 
behavioral abnormalities have been shown to be caused by loss of expression of these genes38. Based on the two 
PWS associated phenotypes, i.e., obesity and hypogonadism that are known to affect bone mass, few or all of these 
genes could be implicated in bone growth disorders. Indeed, PWS is associated with a decrease in bone density 
and an increased risk of fractures37. A decreased expression of these genes in the PWS leads to osteopenia and 
given that in our autism model there is ~2-fold increase in the expression of these genes, these mice would have 
been expected to have an increase in bone mass. In contrast to the above mentioned expected phenotype we 
observed osteopenia in patDp/+ mouse model a fact consistent with the bone phenotype observed in the autism 
patients. Therefore, it seems likely that effect of genes involved in the PWS is dominated by the negative effect of 
another gene(s) in this locus, the identity of which can only be speculated at the present time.
Three genes, Gabrα5, Gabrγ3, Gabrβ3, that are part of the Gamma-Aminobutyric Acid (GABA) receptor 
complex are most upregulated in the patDp/+ mice. GABA receptors mediate signals of the neurotransmitter 
GABA39. Osteoblasts constitutively express metabotropic GABAB receptor subunits and not the majority of the 
GABAA receptor subunits to which the Gabrα5, Gabrγ3, Gabrβ3 in the patDp/+ locus belong39, 40. However, at 
least one of these genes, Gabrγ3 has been shown to be induced in expression when osteoblasts are exposed to 
external stimuli41. Furthermore, it has been demonstrated that GABA can inhibit alkaline phosphatase activity 
and calcium accumulation in osteoblasts42. These evidences suggest that an increased local GABA signaling due 
to the observed increase in the expression of Gabrα5, Gabrγ3, Gabrβ3 may negatively regulate the osteoblast 
functions in the patDp/+ mice. Although ours and earlier studies point toward a cell autonomous defect in the 
osteoblasts we cannot rule out the central signaling, perhaps through GABA, contributing towards the bone phe-
notype observed in the patDp/+ mice. Further studies are needed to identify which of the genes in the patDp/+ 
locus are expressed/induced in the osteoblasts and account for the cell autonomous decrease in osteoblast prolif-
eration or function. This will require duplication or overexpression of genes present in this locus, either alone or 
in combination, to mimic the in vivo expression levels observed in patDp/+ mice.
In summary, we have shown the existence of a low bone mass phenotype in a mouse model of autism. Our 
results reveal an isolated decrease in osteoblast function and bone formation that accounts for this low bone mass 
phenotype and that osteoblasts from the patDp/+ mice have a cell autonomous decrease in their proliferation 
and differentiation. Given that autism patients often show low bone density and increased risk of fractures these 
results lay a foundation for development of therapies that can be used to treat bone disorders using this mouse 
model.
Materials and Methods
Animals. Studies were performed in accordance with appropriate guidelines of the Wellcome Trust Sanger 
Institute and the United Kingdom Home Office. All the experiments were performed under the home office 
project license number PPL 80/2479 and were approved by the Wellcome Trust Sanger Institute Animal Ethics 
Committee. Generation of Dp/+ mice has been described previously26. Heterozygous Dp/+ female or male mice 
were used for all experiments. These were generated using a Dp/+ male mouse and a wild type C57Bl/6 N female 
mouse and littermate controls were used for all analysis. The wild type C57Bl/6 N mice for breeding were obtained 
from in-house wild type colonies maintained at the Wellcome Trust Sanger Institute research support facility.
Micro-computed tomography (µCT) analysis of long bones. Trabecular bone and cortical architec-
ture of the proximal tibia (secondary spongiosa) was assessed using a µCT system (Skyscan 1172). Tibia bone 
specimen was stabilized with gauze in a 2 ml centrifuge tube filled with 70% ethanol and fastened in the specimen 
holder of the µCT scanner. One hundred µCT slices, corresponding to a 1.05 mm region distal from the growth 
plate, were acquired at an isotropic spatial resolution of 10.5 µm. A global thresholding technique was applied 
to binarize gray-scale µCT images where the minimum between the bone and bone marrow peaks in the voxel 
gray value histogram was chosen as the threshold value. The trabecular bone compartment was segmented by 
a semi-automatic contouring method and subjected to a model-independent morphological analysis43 by the 
standard software provided by the manufacturer of the µCT scanner. 3D morphological parameters, including 
model independent measures by distance transformation (DT) of bone volume fraction (BV/TV), Tb.Th. (tra-
becular thickness), Tb.N. (trabecular number), Tb.Sp. (trabecular separation) and connectivity density (Conn.D) 
were evaluated. The Conn.D is a quantitative description of the trabecular connection44, 45.
Histology and histomorphometry of vertebra and long bone. Histological analyses were performed 
on femur and vertebral column specimens collected from 4 weeks-old mice using undecalcified sections stained 
for bone mass, osteoblasts and osteoclasts analysis as described previously46. Static and dynamic histomor-
phometric analyses were performed according to standard protocols using the Osteomeasure Analysis System 
(Osteometrics, Atlanta).
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Cell Cultures. Bromodeoxy Uridine (BrdU) cell proliferation assay. Primary calvarial osteoblasts from WT 
and patDp/+ mice at 70% to 80% confluence were trypsinized, and 5000 cells/well were seeded in 96-well plate in 
alpha-MEM supplemented with 10% fetal bovine serum (FBS). After 24 hours cells were left for another 24 hours 
in alpha-MEM supplemented with 0.5% FBS. For the last 4 hours of the 24-hour stimulation period, the cells were 
pulsed with BrdU. BrdU incorporation was measured using ELISA kit (Roche, IN, USA).
Alkaline phosphatase (ALP) activity assay. Primary calvarial osteoblasts from WT and patDp/+ mice at approx-
imately 80% confluence were trypsinized, and 5000 cells/well were seeded onto 96-well plates. Cells from WT and 
patDp/+ mice were cultured for 48 hours in osteoblast differentiation medium containing alpha-MEM supple-
mented with 10% FBS, 10 mM beta-glycerophosphate, 50 mg/mL of ascorbic acid, and 1% penicillin/streptomy-
cin. At the end of incubation period, total ALP activity was measured using p-nitrophenylphosphate (PNPP) as 
substrate, and absorbance was read at 405 nm (SensoLyte® pNPP Alkaline Phosphatase Assay kit, AnaSpec, Inc.).
Mineralization assay. Primary osteoblast cells were seeded onto 12-well plates (25,000 cells/well) in osteoblast 
differentiation medium. Osteoblasts from WT and patDp/+ mice were cultured for 21 days with a medium 
change every 48 hours. At the end of the experiment, cells were washed with PBS and fixed with 4% paraformal-
dehyde in PBS for 15 minutes. Alizarin red-S was used for staining mineralized nodules.
Bioassays. Serum was prepared using BD Vacutainer® SSTTM, snap frozen in liquid nitrogen and stored 
at −80 °C until analyzed. Serum osteocalcin and Ctx levels were measured using ELISA assays as described 
previously47.
Molecular studies. Total RNA was isolated from either long bone flushed of bone marrow or primary cal-
varial osteoblasts. Real-time PCR was performed on DNase I-treated total RNA converted to cDNA using appro-
priate primers and standard protocols. β-Actin amplification was used as an internal control. Genotypes of all the 
mice were determined by PCR. All primer sequences are listed on Supplementary Table 1.
Statistical analysis. Results are given as mean ± standard error. Statistical Analysis was performed by 
Student’s t-test between two groups and one-way ANOVA followed by Newman-keuls posthoc test for more than 
two groups. All panels in Figs 1–4 *p < 0.05 and **p < 0.01 versus WT.
Data availability. All the mouse strains, experimental tools and raw data present in the manuscript are 
available upon request.
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